Immunic (NASDAQ:IMUX) Earns "Buy" Rating from D. Boral Capital

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reissued by D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

IMUX has been the subject of a number of other research reports. B. Riley restated a "buy" rating and issued a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. Finally, Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $11.60.

Immunic Price Performance

Shares of Immunic stock traded down $0.01 on Wednesday, hitting $0.70. 747,317 shares of the company's stock traded hands, compared to its average volume of 962,218. The firm's 50-day moving average price is $0.91 and its two-hundred day moving average price is $1.00. The stock has a market capitalization of $67.07 million, a PE ratio of -0.57 and a beta of 1.48. Immunic has a one year low of $0.56 and a one year high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). On average, analysts forecast that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. acquired a new position in Immunic in the 4th quarter worth $37,000. Barclays PLC acquired a new position in Immunic in the 4th quarter worth $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after purchasing an additional 96,894 shares during the period. Bridgeway Capital Management LLC boosted its stake in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after purchasing an additional 22,200 shares during the period. Finally, Jane Street Group LLC boosted its stake in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.